Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.

PubWeight™: 0.97‹?› | Rank: Top 15%

🔗 View Article (PMID 17620552)

Published in Neurology on July 10, 2007

Authors

Kevin M Biglan1, Robert G Holloway, Michael P McDermott, Irene H Richard, Parkinson Study Group CALM-PD Investigators

Author Affiliations

1: University of Rochester, Department of Neurology, Rochester, NY 14620, USA. kevin.biglan@ctcc.rochester.edu

Articles citing this

Hallucinations in Parkinson disease. Nat Rev Neurol (2009) 1.13

Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research. Maturitas (2010) 0.93

Many Faces of Parkinson's Disease: Non-Motor Symptoms of Parkinson's Disease. J Mov Disord (2015) 0.90

Dopamine-induced nonmotor symptoms of Parkinson's disease. Parkinsons Dis (2011) 0.88

Postural abnormality as a risk marker for leg deep venous thrombosis in Parkinson's disease. PLoS One (2013) 0.82

Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study. Eur J Clin Pharmacol (2011) 0.80

Renal dopaminergic system: Pathophysiological implications and clinical perspectives. World J Nephrol (2015) 0.79

Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.79

Psychosis assessment in early-stage Parkinson's disease: comparing Parkinson's psychosis questionnaire with the brief psychiatric rating scale in a portuguese sample. Parkinsons Dis (2012) 0.78

Sleep-related falling out of bed in Parkinson's disease. J Clin Neurol (2012) 0.78

Parkinson's disease between internal medicine and neurology. J Neural Transm (Vienna) (2015) 0.77

Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Mov Disord (2011) 0.76

New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis (2011) 0.76

The benefits of pramipexole selection in the treatment of Parkinson's disease. Neurol Sci (2014) 0.76

Causes and factors related to dopamine agonist withdrawal in Parkinson's disease. Brain Behav (2016) 0.75

Pramipexole and its extended release formulation for Parkinson's disease. J Cent Nerv Syst Dis (2011) 0.75

Articles by these authors

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain (2005) 11.80

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89

Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA (2012) 5.40

Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord (2004) 4.83

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain (2003) 4.24

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol (2011) 4.23

HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20

Association between stroke center hospitalization for acute ischemic stroke and mortality. JAMA (2011) 3.68

Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol (2003) 2.81

Proactive palliative care in the medical intensive care unit: effects on length of stay for selected high-risk patients. Crit Care Med (2007) 2.76

A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke (2009) 2.74

Financial anatomy of neuroscience research. Ann Neurol (2006) 2.71

Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain (2013) 2.58

p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54

Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain (2009) 2.49

Human herpesvirus (HHV)-6 and HHV-7 infections in pregnant women. J Infect Dis (2007) 2.29

Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28

Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain (2006) 2.23

An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord (2007) 2.17

Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst (2011) 2.03

The motor neuron response to SMN1 deficiency in spinal muscular atrophy. Muscle Nerve (2014) 2.02

A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01

High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol (2011) 1.95

An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94

High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol (2013) 1.90

Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain (2012) 1.88

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain (2010) 1.84

Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. Pain (2008) 1.82

Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol (2004) 1.79

Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78

Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol (2013) 1.56

Financing of U.S. biomedical research and new drug approvals across therapeutic areas. PLoS One (2009) 1.55

Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry (2003) 1.53

Cognitive fatigue during a test requiring sustained attention: a pilot study. Mult Scler (2003) 1.53

Health state preferences and decision-making after malignant middle cerebral artery infarctions. Neurology (2010) 1.52

Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7). J Pediatr (2004) 1.49

Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45

Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics (2008) 1.44

Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther (2011) 1.42

Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42

The idiopathic intracranial hypertension treatment trial: design considerations and methods. J Neuroophthalmol (2014) 1.40

Pain intensity rating training: results from an exploratory study of the ACTTION PROTECCT system. Pain (2016) 1.39

Human herpesvirus 6 (HHV6) DNA persistence and reactivation in healthy children. J Pediatr (2004) 1.37

An approach to evaluating the therapeutic misconception. IRB (2009) 1.35

Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol (2011) 1.32

Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology (2012) 1.31

Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry (2008) 1.27

Evidence, preferences, recommendations--finding the right balance in patient care. N Engl J Med (2012) 1.26

Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 1.24

Direct estimation of the area under the receiver operating characteristic curve in the presence of verification bias. Stat Med (2009) 1.23

Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol (2013) 1.22

Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve (2013) 1.20

Sex differences in outcome after mild traumatic brain injury. J Neurotrauma (2010) 1.18

Palliative and end-of-life care in stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 1.17

The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord (2008) 1.12

A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol (2010) 1.10

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology (2012) 1.10

If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials (2011) 1.08

Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol (2011) 1.08

The evolving role and value of libraries and librarians in health care. JAMA (2013) 1.07

Early stroke mortality, patient preferences, and the withdrawal of care bias. Neurology (2012) 1.07

Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females. Arch Neurol (2010) 1.06

Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia. Arch Neurol (2007) 1.06

Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol (2006) 1.04

Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry (2008) 1.04

The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making (2007) 1.03

Characteristics and acquisition of human herpesvirus (HHV) 7 infections in relation to infection with HHV-6. J Infect Dis (2006) 1.03

Symptomatic and palliative care for stroke survivors. J Gen Intern Med (2012) 1.02

Epidermal nerve fiber density, axonal swellings and QST as predictors of HIV distal sensory neuropathy. Muscle Nerve (2004) 1.02

Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord (2007) 1.01

Development and testing of the Parkinson's disease quality of life scale. Mov Disord (2003) 1.01

Research participants' "irrational" expectations: common or commonly mismeasured? IRB (2013) 1.00

Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol (2013) 1.00

Treatment decisions after severe stroke: uncertainty and biases. Stroke (2012) 1.00

The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn Behav Neurol (2004) 0.99

CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomes. Radiology (2002) 0.99

Anxiety rating scales in Parkinson's disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale. Mov Disord (2011) 0.98

A randomized trial comparing long-term and short-term use of umbilical venous catheters in premature infants with birth weights of less than 1251 grams. Pediatrics (2006) 0.97

Risk adjustment of ischemic stroke outcomes for comparing hospital performance: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 0.97

Diagnostic odyssey of patients with myotonic dystrophy. J Neurol (2013) 0.97

Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model. J Womens Health (Larchmt) (2009) 0.97

Psychosocial risk factors for postherpetic neuralgia: a prospective study of patients with herpes zoster. J Pain (2005) 0.97

The relationship between uric acid levels and Huntington's disease progression. Mov Disord (2010) 0.96

Design considerations for a multicenter randomized controlled trial of early surgery for mesial temporal lobe epilepsy. Epilepsia (2010) 0.96

Funding of Parkinson research from industry and US federal and foundation sources. Mov Disord (2009) 0.96

Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitals. Am Heart J (2010) 0.95

Effect of L-methionine on hot flashes in postmenopausal women: a randomized controlled trial. Menopause (2009) 0.95

Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain (2012) 0.95

Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain (2010) 0.95

Palliative Care Needs in the Neuro-ICU. Crit Care Med (2015) 0.95

Racial differences in mortality among patients with acute ischemic stroke: an observational study. Ann Intern Med (2011) 0.95

Effects of L-isoleucine and L-valine on hot flushes and serum homocysteine: a randomized controlled trial. Obstet Gynecol (2008) 0.94

The value of patient-reported health status in predicting short-term outcomes after coronary artery bypass graft surgery. Med Care (2002) 0.94

Hemicraniectomy for middle-cerebral-artery stroke. N Engl J Med (2014) 0.92

Ethics of sham surgery: perspective of patients. Mov Disord (2008) 0.92

Burdens and benefits of placebos in antidepressant clinical trials: a decision and cost-effectiveness analysis. Am J Psychiatry (2003) 0.91

Challenges in assessing hospital-level stroke mortality as a quality measure: comparison of ischemic, intracerebral hemorrhage, and total stroke mortality rates. Stroke (2012) 0.91

Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study. Mov Disord (2011) 0.91